Current Report Filing (8-k)
June 14 2023 - 4:06PM
Edgar (US Regulatory)
0000749647
false
0000749647
2023-06-14
2023-06-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): June 14, 2023 (June 14, 2023)
IMUNON,
INC.
(Exact
name of registrant as specified in its Charter)
| Delaware |
|
001-15911 |
|
52-1256615 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
| 997
Lenox Drive, Suite 100, Lawrenceville, NJ |
|
08648-2311 |
| (Address
of principal executive offices) |
|
(Zip
Code) |
(609)
896-9100
(Registrant’s
telephone number, including area code)
N/A
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
| ☐ |
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act
| Title
of each class |
|
Trading
symbol(s) |
|
Name
of each exchange on which registered |
Common
stock, par value $0.01 per share |
|
IMNN |
|
The
Nasdaq Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933
(§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers
On
June 14, 2023, Augustine Chow, Ph.D., a Class I member of the Board of Directors (the “Board”) of Imunon, Inc. (the “Registrant”),
retired from the Registrant’s Board upon conclusion of the 2023 Annual Meeting of Stockholders (the “Meeting”). Dr.
Chow has served on the Registrant’s Board since March 2007 and was a member of the Board’s Compensation and Audit Committees.
Dr. Chow’s current term as a Class I Board member was scheduled to end as of the Meeting. With Dr. Chow reaching 70 years
of age in 2023 and having served on the Board for 16 years, the Registrant chose not to include Dr. Chow in its slate of nominees
for re-election at the Meeting. Dr. Chow’s retirement from the Board was not because of any disagreement with management or the
Board relating to the Registrant’s operations, policies or practices.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
IMUNON,
INC. |
| |
|
|
| Dated:
June 14, 2023 |
By: |
/s/
Jeffrey W. Church |
| |
|
Jeffrey
W. Church |
| |
|
Executive
Vice President and Chief Financial Officer |
Celsion (NASDAQ:CLSN)
Historical Stock Chart
From Apr 2024 to May 2024
Celsion (NASDAQ:CLSN)
Historical Stock Chart
From May 2023 to May 2024
